The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States
Open Access
- 22 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 15 (1), 1-9
- https://doi.org/10.1186/s13023-020-01387-8
Abstract
Spinal muscular atrophy (SMA) is a rare neuromuscular disease with a rapidly evolving treatment landscape. To better meet the needs of trial sponsors and the patient community in the United States (US) in this evolving context, Cure SMA established a clinical trial readiness program for new and prospective SMA clinical trial sites. Program development was informed by a review of the SMA clinical trial landscape, successful NMD trial and care networks, and factors important to effective trial conduct in SMA. The program was piloted in 2018 with a virtual site readiness evaluation, a trial readiness toolkit, and a readiness program for physical therapists and clinical evaluators. Nine US research hospitals participated in the pilot. Cure SMA evaluated the pilot program and resources through feedback surveys, which supported the program’s relevance and value. Since 2018, the program has been expanded with additional sites, new best practices toolkits, and workshops. In partnership with Cure SMA, SMA Europe is also extending programming to European countries. The program is significant as an example of a patient advocacy group working successfully with pharmaceutical companies, other patient advocacy organizations, and research hospitals to promote trial readiness, and may serve as a model for organizations in other regions and diseases.Keywords
This publication has 35 references indexed in Scilit:
- An observational study of functional abilities in infants, children, and adults with type 1 SMANeurology, 2018
- Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature reviewOrphanet Journal of Rare Diseases, 2017
- Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4Journal of Neurology, Neurosurgery & Psychiatry, 2017
- Spinal Muscular AtrophyNeurologic Clinics, 2015
- Spinal Muscular Atrophy Therapeutics: Where do we Stand?Neurotherapeutics, 2015
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- Amyotrophie spinale infantile Étude multicentrique prospective et longitudinale de 168 cas suivis 4 ansBulletin de l'Académie Nationale de Médecine, 2005
- Quantitative Analysis of Survival Motor Neuron Copies: Identification of Subtle SMN1 Mutations in Patients with Spinal Muscular Atrophy, Genotype-Phenotype Correlation, and Implications for Genetic CounselingAmerican Journal of Human Genetics, 1999
- Natural History in Proximal Spinal Muscular AtrophyArchives of Neurology, 1995
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995